Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCT510 + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
SCT510 + paclitaxel + carboplatin is a combination regimen comprising three agents: - SCT510, which is an experimental biosimilar of bevacizumab, - paclitaxel, a microtubule inhibitor, and - carboplatin, a platinum-based alkylating agent. The combination aims to leverage multiple mechanisms of action against cancer. Bevacizumab (the reference drug for SCT510) is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing tumor angiogenesis. Paclitaxel disrupts microtubule function and inhibits cell division, while carboplatin induces DNA crosslinking and apoptosis in rapidly dividing cells. This combination is used primarily for the treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancers, particularly in the frontline setting following surgical resection. The regimen is being investigated in clinical trials for efficacy and safety compared to standard of care combinations[5][8].
- Other names
- SCT510 + paclitaxel + carboplatin
02
Targets
Beyond the preview
Go deeper on SCT510 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCT510 + paclitaxel + carboplatin.